UnitedHealth Group
UNH
$429.09
+1.05%
UnitedHealth Group is a diversified healthcare company that provides health insurance and healthcare services through its UnitedHealthcare and Optum segments, serving approximately 51 million members globally. As the largest private health insurer in the U.S., it combines massive scale in insurance with a vertically integrated healthcare services platform spanning pharmacy benefits, outpatient care, and data analytics. The current investor narrative centers on the company's operational recovery from a challenging 2024, driven by better-than-expected Medicare reimbursement rates, AI-driven efficiency gains, and a strong rebound in earnings, though an ongoing DOJ investigation and regulatory overhang continue to fuel debate.…
UNH
UnitedHealth Group
$429.09
Related headlines
Investment Opinion: Should I buy UNH Today?
Rating: Hold. UnitedHealth is a high-quality business with strong revenue growth and cash flow, but the stock's 41.8% YTD rally and unresolved DOJ investigation create an unfavorable risk/reward at current levels. The analyst consensus is Buy, but the lack of explicit price targets limits upside visibility.
Supporting Evidence: Revenue grew 12.3% YoY in Q4, and TTM revenue is $447.6B. The forward P/E of 20.2x implies 23% earnings growth, which is achievable if margins normalize. Free cash flow of $16.1B supports a 2.64% dividend yield. However, the trailing P/E of 24.95x is above the industry average of 22x, and the Q4 operating margin of 0.3% shows how fragile profitability is. The stock has already rallied 41.8% in the past year, pricing in much of the recovery.
Risks & Conditions: The two biggest risks are margin recovery failure and DOJ investigation escalation. This Hold would upgrade to Buy if the forward P/E compresses below 18x (implying a price below $620 based on consensus EPS of $34.39) or if the DOJ investigation is resolved favorably. It would downgrade to Sell if Q1 2026 earnings show another quarter of sub-1% operating margins or if the DOJ announces formal charges. Valuation verdict: UNH is fairly valued relative to its history (trailing P/E near the middle of its 5-year range of 18-30x) but slightly overvalued relative to peers.
Sign up to view all
UNH 12-Month Price Forecast
UnitedHealth's outlook is balanced between a strong operational recovery and significant near-term risks. The base case of gradual margin improvement and resolution of the DOJ overhang is most probable, but the wide range of outcomes reflects high uncertainty. The stock's 41.8% YTD rally already prices in a successful recovery, leaving limited upside unless margins surprise to the upside. I would upgrade to bullish if Q1 2026 operating margin exceeds 6% or the DOJ investigation is resolved, and downgrade to bearish if margins remain below 4% or negative DOJ news emerges.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $557.82 and implied upside of +30.0% versus the current price.
Average Target
$557.82
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$343 - $558
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation leaning bullish. All recent ratings from major firms (Mizuho, JP Morgan, Truist, Barclays, Wells Fargo, Leerink, RBC, Jefferies, UBS, Oppenheimer) are Buy or Outperform equivalents, indicating strong institutional conviction. The average EPS estimate for the current fiscal year is $34.39, with a range of $33.45 to $35.55, and average revenue estimate of $549.2 billion. While specific price targets are not provided, the consensus EPS implies a forward P/E of 20.2x at the current price, suggesting analysts see further upside if earnings materialize. The absence of explicit price targets limits the ability to calculate implied upside, but the uniform bullishness from analysts points to a positive outlook. The narrow range of EPS estimates (low $33.45 to high $35.55) reflects relatively high conviction among analysts, with a spread of only 6.3% from low to high. This tight range suggests that analysts have a consistent view of the company's near-term earnings trajectory, reducing uncertainty. The recent upgrades and reiterations of Buy ratings, particularly after the Q4 earnings dip, signal that the sell-side views the weakness as temporary and expects a strong rebound. The lack of any Hold or Sell ratings among the recent actions reinforces the bullish consensus, though investors should be aware that the DOJ investigation remains a wild card that could alter sentiment.
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a compelling bull case built on strong revenue growth, favorable Medicare rates, robust free cash flow, and unanimous analyst support. However, the bear case highlights significant risks: a disastrous Q4 earnings miss with razor-thin margins, an unresolved DOJ investigation, and a valuation premium to peers. The single most important tension is whether the Q4 margin compression is a temporary blip or the start of a structural profitability decline. If margins recover as analysts expect, the stock is attractively valued on forward earnings; if not, the premium P/E could contract sharply. Currently, the bull case has stronger evidence given the operational recovery trajectory and analyst conviction, but the DOJ risk remains a wild card.
Bullish
- Strong Revenue Growth: Revenue grew 12.3% YoY in Q4 2025 to $113.2B, and TTM revenue reached $447.6B, driven by membership growth and higher reimbursement rates. This consistent double-digit expansion underscores the company's scale and pricing power.
- Favorable Medicare Rate Decision: The final Medicare Advantage rate decision was favorable, boosting earnings visibility for 2026. This catalyst, combined with AI-driven efficiency gains, has driven the stock up 41.8% over the past year.
- Strong Free Cash Flow: TTM free cash flow of $16.1B provides ample liquidity for dividends (yield 2.64%) and share buybacks. The payout ratio of 65.7% is sustainable, supporting a reliable income stream.
- Analyst Consensus Bullish: All 15 analysts covering UNH rate it Buy or Outperform, with a tight EPS estimate range ($33.45-$35.55) reflecting high conviction. The forward P/E of 20.2x implies expected earnings growth of ~23%.
Bearish
- Q4 Earnings Miss and Margin Compression: Q4 2025 net income was only $10M (EPS $0.01) due to an operating loss, with gross margin falling to 16.3% from 21.1% a year earlier. The operating margin of 0.3% in Q4 highlights significant medical cost pressure.
- DOJ Investigation Overhang: An ongoing DOJ investigation creates regulatory uncertainty that could lead to fines, business restrictions, or reputational damage. This unresolved risk tempers the bullish sentiment and could trigger a selloff if negative news emerges.
- Valuation Premium to Peers: The trailing P/E of 24.95x is a 13.4% premium to the healthcare plans industry average of ~22x. While justified by scale, this premium leaves limited margin for error if earnings disappoint.
- Elevated Medical Loss Ratio: The full-year operating margin of ~5.5% is below the industry average, reflecting higher medical costs. This trend could persist if utilization rates remain elevated, pressuring profitability.
UNH Technical Analysis
UnitedHealth is in a powerful sustained uptrend, with the stock up 41.8% over the past year and currently trading at 97.8% of its 52-week range (current price $424.62 vs. 52-week high $434.30). This positioning near the highs reflects strong momentum and investor confidence, though it also suggests the stock may be somewhat extended after a sharp recovery from its 52-week low of $234.60. The 1-year price change of +41.8% significantly outperforms the S&P 500's +20.6% over the same period, highlighting UNH's relative strength. Short-term momentum is accelerating, with the stock gaining 4.2% in the past month and 39.5% over the past three months, compared to the S&P 500's 4.1% and 11.1% respectively. The 3-month change of 39.5% is nearly in line with the 1-year change, indicating that most of the annual gains have occurred in the last quarter, which could signal a momentum-driven rally that may be due for a pause. The relative strength over 3 months is 28.4%, confirming strong outperformance. Key technical support lies near the 52-week low of $234.60, while resistance is at the 52-week high of $434.30. A breakout above $434.30 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below recent support around $400 could indicate a pullback. The stock's beta of 0.63 indicates it is significantly less volatile than the market, making it a lower-risk holding that may lag during sharp market rallies but provide downside protection.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$235-$434
Price range past year
Annual Return
+41.1%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | +5.0% | +1.0% |
| 3m | +36.6% | +7.9% |
| 6m | +28.1% | +8.5% |
| 1y | +41.1% | +20.1% |
| ytd | +27.6% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
Revenue growth remains robust, with the most recent quarter (Q4 2025) reporting revenue of $113.2 billion, up 12.3% year-over-year. This marks a deceleration from the 14.4% growth seen in Q3 2025 but still represents strong double-digit expansion. The trailing twelve-month revenue reached approximately $447.6 billion, driven by premium growth in UnitedHealthcare and continued expansion of Optum's services. The revenue trajectory is solidly upward, supported by membership growth and higher reimbursement rates, though the pace of acceleration may moderate. Profitability has been volatile, with Q4 2025 net income of just $10 million (EPS $0.01) due to a $938 million income tax benefit that masked an operating loss. However, on a trailing twelve-month basis, net income was $12.1 billion, and the gross margin of 16.3% in Q4 was compressed from 21.1% a year earlier, reflecting higher medical costs. The operating margin of 0.3% in Q4 was unusually low, but the full-year operating margin was approximately 5.5%, which is below the industry average for managed care companies, indicating margin pressure from elevated medical loss ratios. The balance sheet is solid, with a debt-to-equity ratio of 0.83 and free cash flow of $16.1 billion over the trailing twelve months, providing ample liquidity for dividends and share buybacks. The current ratio of 0.79 is below 1.0, which is typical for insurers due to the timing of premium collections and claims payments, and does not signal distress. Return on equity of 12.8% is healthy, though down from prior years, reflecting the earnings drag from the Q4 loss.
Quarterly Revenue
$113.2B
2025-12
Revenue YoY Growth
+12.3%
YoY Comparison
Gross Margin
16.3%
Latest Quarter
Free Cash Flow
$16.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Since net income is positive on a trailing twelve-month basis (TTM net income of $12.1 billion), the primary valuation metric is the P/E ratio. The trailing P/E is 24.95x, while the forward P/E is 20.24x, implying the market expects earnings growth of about 23% over the next year. The gap between trailing and forward P/E suggests that the market is pricing in a significant earnings recovery from the depressed Q4 2025 levels. Compared to the healthcare plans industry average P/E of approximately 22x, UNH's trailing P/E of 24.95x represents a 13.4% premium. This premium is justified by UNH's superior scale, diversified business model (insurance + Optum services), and consistent revenue growth, though the recent earnings volatility tempers the premium. Historically, UNH's trailing P/E has ranged from roughly 18x to 30x over the past five years. The current 24.95x is near the middle of that range, suggesting the stock is fairly valued relative to its own history. However, the forward P/E of 20.24x is at the lower end of the historical range, indicating that if the company delivers on earnings expectations, the stock could be attractively priced. The P/S ratio of 0.67x is low relative to historical levels (typically 1.5-2.0x), but this is due to the high revenue base and low net margin; the P/S is less relevant for profitability analysis.
PE
25.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -80x~7510x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is margin compression, as evidenced by Q4 2025's operating margin of just 0.3% and gross margin falling to 16.3% from 21.1% a year ago. This was driven by elevated medical costs, and if utilization rates remain high, full-year operating margins could stay below the 5.5% TTM level. Additionally, the debt-to-equity ratio of 0.83 is manageable but not negligible, and the current ratio of 0.79 is typical for insurers but could become a concern if cash flow weakens. The Q4 net income of only $10M on $113.2B revenue highlights how sensitive earnings are to cost trends.
Market & Competitive Risks: The stock's beta of 0.63 indicates low market correlation, but it is not immune to sector rotation or regulatory shocks. The DOJ investigation is a company-specific overhang that could lead to fines or business restrictions, and any negative development could erase the 41.8% YTD gain. Valuation risk is present: the trailing P/E of 24.95x is a 13.4% premium to the industry average, and if earnings fail to rebound, the multiple could contract. Recent news highlights that the stock's 80% rally from its low makes risk-reward less attractive, and insider selling by Greg Abel (Warren Buffett's successor) signals caution at current levels.
Worst-Case Scenario: In a worst-case scenario, the DOJ investigation uncovers significant compliance issues leading to heavy fines or restrictions on Medicare Advantage operations, while medical costs continue to rise, causing another quarter of near-zero earnings. This could trigger a wave of analyst downgrades and a sharp de-rating. From the current price of $424.62, the realistic downside is to the 52-week low of $234.60, representing a potential loss of -44.7%. This scenario would require a confluence of negative events, but the stock's recent rally leaves it vulnerable to a 30-40% correction if fundamentals deteriorate.
FAQ
The primary risk is margin compression: Q4 2025 operating margin fell to 0.3% from 7.7% a year earlier, driven by elevated medical costs. If this persists, earnings could remain depressed. The second risk is the DOJ investigation, which could result in fines or business restrictions and create headline risk. Third, valuation risk: the trailing P/E of 24.95x leaves limited room for error if earnings disappoint. Fourth, regulatory risk: changes to Medicare Advantage reimbursement rates could impact revenue growth. The most severe risk is a combination of margin pressure and DOJ escalation, which could drive the stock down 30-40% to the 52-week low of $234.60.
Over the next 12 months, UNH is expected to trade in a range of $300 to $520, with a base case target of $420-$470 (50% probability) assuming gradual margin improvement and no major DOJ news. The bull case (30% probability) targets $480-$520 if margins normalize and the DOJ investigation is resolved favorably. The bear case (20% probability) sees the stock falling to $300-$350 if margins remain weak and DOJ issues escalate. The base case is most likely, supported by analyst EPS estimates of $34.39, but the wide range reflects high uncertainty. Investors should monitor Q1 2026 earnings and DOJ developments for direction.
UNH's trailing P/E of 24.95x is a 13.4% premium to the healthcare plans industry average of ~22x, suggesting it is slightly overvalued relative to peers. However, the forward P/E of 20.2x is at the lower end of its 5-year historical range (18-30x), implying the market expects significant earnings growth (~23%) to justify the current price. The P/S ratio of 0.67x is low historically, but this is due to high revenue and low net margins. Overall, UNH is fairly valued relative to its own history but commands a premium to peers that is justified by its scale and diversification. The market is pricing in a successful margin recovery; if that fails, the stock could be overvalued.
UnitedHealth is a high-quality business with strong revenue growth (12.3% YoY) and robust free cash flow ($16.1B TTM), but the stock's 41.8% YTD rally and unresolved DOJ investigation make the risk/reward less attractive at current levels. The analyst consensus is Buy, but the lack of explicit price targets limits upside visibility. The biggest downside risk is margin compression—Q4 2025 operating margin was just 0.3%—which could persist and lead to earnings disappointment. For long-term investors with a 3-5 year horizon, UNH is a solid core holding, but near-term buyers may face volatility. It is a good buy on pullbacks below $380, where the forward P/E would be below 18x.
UNH is best suited for long-term investment (3-5 years) due to its defensive characteristics (beta 0.63), reliable dividend yield (2.64%), and dominant position in healthcare. Short-term trading is riskier given the stock's 41.8% YTD rally and sensitivity to quarterly earnings and DOJ news. The low beta means it may underperform in strong market rallies but provides downside protection. For long-term investors, the current valuation is reasonable on forward earnings, and the dividend growth story is intact. A minimum holding period of 3 years is recommended to ride out regulatory and margin cycles. Short-term traders should focus on earnings events and DOJ headlines for volatility plays.